MXPA00011389A - New macrolide - Google Patents
New macrolideInfo
- Publication number
- MXPA00011389A MXPA00011389A MXPA/A/2000/011389A MXPA00011389A MXPA00011389A MX PA00011389 A MXPA00011389 A MX PA00011389A MX PA00011389 A MXPA00011389 A MX PA00011389A MX PA00011389 A MXPA00011389 A MX PA00011389A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- alkyl
- group
- compound
- aryl
- Prior art date
Links
- 239000003120 macrolide antibiotic agent Substances 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 179
- 239000011780 sodium chloride Substances 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 239000000651 prodrug Substances 0.000 claims abstract description 18
- 229940002612 prodrugs Drugs 0.000 claims abstract description 18
- 206010060945 Bacterial infection Diseases 0.000 claims abstract description 13
- 206010037075 Protozoal infection Diseases 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 239000012453 solvate Substances 0.000 claims abstract description 9
- -1 aikenyl Chemical group 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 31
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 125000005418 aryl aryl group Chemical group 0.000 claims description 24
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000003342 alkenyl group Chemical group 0.000 claims description 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 19
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 19
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000000304 alkynyl group Chemical group 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 150000001412 amines Chemical class 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 239000007818 Grignard reagent Substances 0.000 claims description 10
- 125000005024 alkenyl aryl group Chemical group 0.000 claims description 10
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 10
- 125000005025 alkynylaryl group Chemical group 0.000 claims description 10
- 150000004795 grignard reagents Chemical class 0.000 claims description 10
- 241000251468 Actinopterygii Species 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 7
- 125000004429 atoms Chemical group 0.000 claims description 7
- 230000002378 acidificating Effects 0.000 claims description 6
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000001590 oxidative Effects 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 4
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical group [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004434 sulfur atoms Chemical group 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- 201000009910 diseases by infectious agent Diseases 0.000 description 36
- 239000000243 solution Substances 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 230000002194 synthesizing Effects 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000012267 brine Substances 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 239000012043 crude product Substances 0.000 description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 15
- 239000000460 chlorine Chemical group 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 14
- 239000012047 saturated solution Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 241000606856 Pasteurella multocida Species 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000007792 addition Methods 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 229940041033 Macrolides Drugs 0.000 description 7
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 7
- 238000001819 mass spectrum Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001293418 Mannheimia haemolytica Species 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 230000035695 Efflux Effects 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000845 anti-microbial Effects 0.000 description 3
- CHIHQLCVLOXUJW-UHFFFAOYSA-N benzoic anhydride Chemical compound C=1C=CC=CC=1C(=O)OC(=O)C1=CC=CC=C1 CHIHQLCVLOXUJW-UHFFFAOYSA-N 0.000 description 3
- AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical group O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- ZGIKWINFUGEQEO-UHFFFAOYSA-N 3-bromoquinoline Chemical compound C1=CC=CC2=CC(Br)=CN=C21 ZGIKWINFUGEQEO-UHFFFAOYSA-N 0.000 description 2
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N Allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241001148536 Bacteroides sp. Species 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 229940038705 Chlamydia trachomatis Drugs 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 229940047650 Haemophilus influenzae Drugs 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 206010038683 Respiratory disease Diseases 0.000 description 2
- 206010040872 Skin infection Diseases 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 229940076185 Staphylococcus aureus Drugs 0.000 description 2
- 229940031000 Streptococcus pneumoniae Drugs 0.000 description 2
- 229940076156 Streptococcus pyogenes Drugs 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N Tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000009632 agar plate Methods 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 244000052616 bacterial pathogens Species 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-M 2-(dimethylamino)acetate Chemical class CN(C)CC([O-])=O FFDGPVCHZBVARC-UHFFFAOYSA-M 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- UCUNFLYVYCGDHP-UHFFFAOYSA-N 2-azaniumyl-4-methylsulfonylbutanoate Chemical compound CS(=O)(=O)CCC(N)C(O)=O UCUNFLYVYCGDHP-UHFFFAOYSA-N 0.000 description 1
- 108020005097 23S Ribosomal RNA Proteins 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical class C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N 5-hydroxylysine Chemical compound NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 206010000210 Abortion Diseases 0.000 description 1
- 206010000269 Abscess Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical class C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N Azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229940092524 Bartonella henselae Drugs 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 229940052491 Bordetella pertussis Drugs 0.000 description 1
- 241001148534 Brachyspira Species 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 206010008323 Cervicitis Diseases 0.000 description 1
- 229940038704 Clostridium perfringens Drugs 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010742 Conjunctivitis infective Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241001518260 Corynebacterium minutissimum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000605721 Dichelobacter nodosus Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 206010019375 Helicobacter infection Diseases 0.000 description 1
- 229940037467 Helicobacter pylori Drugs 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 206010023332 Keratitis Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid zwitterion Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241001148567 Lawsonia intracellularis Species 0.000 description 1
- 229940115932 Legionella pneumophila Drugs 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 229940041028 Lincosamides Drugs 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010025169 Lyme disease Diseases 0.000 description 1
- 101710019192 MRSA2 Proteins 0.000 description 1
- 101700057214 MSRA Proteins 0.000 description 1
- 208000004396 Mastitis Diseases 0.000 description 1
- 208000010315 Mastoiditis Diseases 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001138504 Mycoplasma bovis Species 0.000 description 1
- 229940013390 Mycoplasma pneumoniae Drugs 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- BFGNHBBJJWESFT-UHFFFAOYSA-N N,N-dimethylformamide;ethoxyethane Chemical compound CCOCC.CN(C)C=O BFGNHBBJJWESFT-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- UBNFODVJIGWGBA-UHFFFAOYSA-N N-chloro-N-propan-2-ylcyclohexanamine Chemical compound CC(C)N(Cl)C1CCCCC1 UBNFODVJIGWGBA-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229940051027 Pasteurella multocida Drugs 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- YGXCETJZBDTKRY-DZCVGBHJSA-N Pristinamycin IA Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N Propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 206010037294 Puerperal pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infection Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 206010040490 Sexually transmitted disease Diseases 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 229940030998 Streptococcus agalactiae Drugs 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 108010015795 Streptogramin B Proteins 0.000 description 1
- 229940041030 Streptogramins Drugs 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N Tert-Butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 206010044008 Tonsillitis Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 208000000143 Urethritis Diseases 0.000 description 1
- 210000001635 Urinary Tract Anatomy 0.000 description 1
- 206010046577 Urinary tract infection Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- AVFUHBJCUUTGCD-UHFFFAOYSA-M [Br-].[Mg+]C Chemical compound [Br-].[Mg+]C AVFUHBJCUUTGCD-UHFFFAOYSA-M 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- CXBNMPMLFONTPO-UHFFFAOYSA-N acetic benzoic anhydride Chemical compound CC(=O)OC(=O)C1=CC=CC=C1 CXBNMPMLFONTPO-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000005661 acute cystitis Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003692 aminobutyric acid Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229940000635 beta-Alanine Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 101700027825 ermB Proteins 0.000 description 1
- 101710037552 ermC Proteins 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 229940013945 gamma-Aminobutyric Acid Drugs 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 244000052637 human pathogens Species 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 101700043910 mefA Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 101700058433 msrA1 Proteins 0.000 description 1
- 101700005326 msrAB Proteins 0.000 description 1
- 101710042628 msrAB1 Proteins 0.000 description 1
- 101710042613 msrAB2 Proteins 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 201000007100 pharyngitis Diseases 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- WQKGAJDYBZOFSR-UHFFFAOYSA-N potassium;propan-2-olate Chemical compound [K+].CC(C)[O-] WQKGAJDYBZOFSR-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 244000079416 protozoan pathogens Species 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical class [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical class CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 102000035402 transmembrane proteins Human genes 0.000 description 1
- 108091005683 transmembrane proteins Proteins 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The invention relates to compounds of Formula 1 and to pharmaceutically acceptable salts, solvates, and prodrugs thereof, wherein X, Y, Z, R<1>, R<2>, R<3>, R<4>, and R<5>are defined herein. The invention further relates to methods of making compounds of Formula 1 and to pharmaceutical compositions comprising compounds of Formula 1. The invention is also related to methods of treating diseases and disorders such as, but not limited to, bacterial and protozoal infections which comprise the administration of a compound of Formula 1, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
Description
NEW MACROLIDES
FIELD OF THE INVENTION
The invention relates to new macrolide derivatives, to pharmaceutical compositions comprising them, and to methods of using them in the treatment or prevention of, for example, bacterial or protozoal infections in mammals, fish or birds.
BACKGROUND OF THE INVENTION
Macrolide antibiotics, which can be used in the treatment or prevention of bacterial or protozoal infections in mammals, fish or birds, include various derivatives of erythromycin A, such as azithromycin, which is commercially available and is mentioned in the U.S. Patents. Nos. 4,474,768 and 4,517,359, both of which are incorporated herein by reference. Examples of additional macrolides are described in: the provisional patent application of E.U.A. No. 60/049348, filed June 11, 1997 (by Brian S. Bronk, Michael A. Letavic, Takushi Kaneko, Bingwei V. Yang, E.A. Glazer, and Hengmiao Cheng); the provisional patent application of E.U.A. No. 60/049348 filed June 11, 1997 (by Brian S. Bronk, Michael A. Letavic, Takushi Kaneko, Bingwei V. Yang, E.A. Glazer, and Hengmiao Cheng); international patent applications WO 98/01571 (Peter Francis Leadlay, James Staunton, Jesus Cortes and Michael Stephen Pacey); WO 98/01546 (Peter Francis Leadlay, James Staunton, and Jesus Cortes); the provisional patent application of E.U.A. No. 60/070343 filed January 2, 1998 (by John P. Dirlam); the provisional patent application of E.U.A. No. 60/097075, filed August 19, 1998 (Hengmiao Cheng, Michael A. Letavic, Carl B. Ziegler, Peter Bertinato, Jason K. Dutra, Brian S. Bronk); and international patent application WO 98/09978, all of which are incorporated herein by reference.
BRIEF DESCRIPTION OF THE INVENTION
The invention relates to new compounds of formula 1:
and its pharmaceutically acceptable salts, solvates and prodrugs, wherein: X is -CH2NR7- or -NR7CHR6-, in which the first line of each of the preceding groups X is attached to Y and the last line of each of the preceding groups X is bonded to carbon C-8; Y is -CH (CH3) -; or X, Y and R can be taken together to form the rest of formula a
Z is selected from the group consisting of -C (O) -, -CH (-OR8) -, and the rest of formula b
R1 is H or a hydroxy protecting group; R2 is -OR13, or R2 and R3 are taken together to form the remainder of formula c
or if X is -NR7CHR6-, R2 and R6 can be taken together to form the remainder of formula d
R3 is -OC (O) R14, or R3, X and Y are taken together to form the residue of formula a, or R3 and R2 are taken together to form the residue of formula c; R is -OR15; R5 is a C2-C8 alkyl group, C2-C8 alkenyl, C2-C8 alkynyl, C2-C8 alkoxyalkyl or C2-C8 alkylthioalkyl branched alpha, optionally substituted with at least one hydroxyl group, a C2-C5 alkyl group branched at alpha, linked to a C5-C8 cycloalkyl group; a C3-C8 cycloalkyl or cycloalkenyl group optionally substituted with at least one moiety selected from the group consisting of methyl, hydroxy, halo and C? -C alkyl groups; or a saturated, or fully or partially unsaturated, heterocycle of 3-6 members, comprising at least one oxygen or sulfur atom and optionally substituted with one or more C C alkyl groups or halogen atoms; R6 is H, or if X is -NR7CHR6-, R6 and R2 can be taken together to form the remainder of formula d; R 7 is selected from the group consisting of H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 8 alkynyl, - (CH 2) m (C 1 -C 6 aryl) and - (CH 2) m (heteroaryl 5-10 members), in which the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the preceding R7 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido , -C (O) R11, -OC (O) R11, -NR11C (O) R12, -C (O) NR11R12, -NR11R12, hydroxy, C-C-alkyl, C-C6-alkoxy, C-C-io aryl and heteroaryl of 5-10 members; R 8 is selected from the group consisting of H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 8 alkynyl, -C (O) R 17, -C (O) NR 17 R 18, - (CH 2) m (C 6 aryl) -C10) and - (CH2) m (5-10 membered heteroaryl), in which the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the preceding R8 groups are optionally substituted with 1 to 3 substituents independently selected from the group which consists of halo, cyano, nitro, trifluoromethyl, azido, -C (O) R11, -OC (O) R11, -R11C (O) R12, -C (O) NR 1R12, -NR11R12, hydroxy, alkyl C? -C6, C6-C6 alkoxy, C6-C6aryl aryl and 5-10 membered heteroaryl; R9 is hydroxy; R10 is selected from the group consisting of H, C -? - C? Alkyl or > C2-C? 0 alkenyl, C2-C10 alkynyl, cyano, -CH2S (O) nR11, -CH2OR11, -CH2NR11R12, - (CH2) m (C6-C8 aryl) and - (CH2) m (5-10 heteroaryl) members), wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the preceding R10 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C- (O) R 11, -OC (O) R 11, -NR 11 C (O) R 12, -C (O) NR 11 R 12, -NR 11 R 12, hydroxy, C C 6 alkyl, C 1 -C 6 alkoxy, C 6 -C 10 aryl and heteroaryl 5- 10 members; each R 11 and R 12 is independently selected from the group consisting of H, CrC 6 alkyl, C 2 -C 6 alkenyl, (CH 2) m (C 6 -C 6 aryl), (CH 2) m (5-10 membered heteroaryl) and alkynyl C2-C10, in which the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the preceding groups R11 and R12 are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, alkyl C Cß and C C β alkoxy; R 13 is selected from the group consisting of H, C -C 10 alkyl, C 2 -C 0 alkenyl, C 2 -C 8 alkynyl, -R 16 (C 6 -C 10 aryl), and -R 16 (5-10 membered heteroaryl) , wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the preceding R13 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C; ) R11, -OC (O) R11, -NR11C (O) R12, -C (O) NR1iR12, -NR11R12, hydroxy, C6 alkyl, alkoxy d-Ce, aryl C6-C? 0 and heteroaryl 5-10 members; R 14 is selected from the group consisting of C 1 -C 10 alkyl, C 2 -C 0 alkenyl, C 2 -C 8 alkynyl, - (CH 2) m (C 6 -C 0 aryl) and - (CH 2) m (heteroaryl 5-10 members), in which the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the preceding R14 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido , -C (O) R11, -OC (O) R11, -NR11C (O) R12, -C (O) NR11R12, -NR11R12, hydroxy, C-C-alkyl, C-C6-alkoxy, Ce-C-aryl and heteroaryl -10 members. R15 is independently selected from the group consisting of H, C1-C10 alkyl, C2-C10 alkenyl, C2-C2 alkynyl, or - (CH2) m (C6-C? 0 aryl) and - (CH2) m (heteroaryl) 5-10 members), wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the preceding R15 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C (O) R 1 \ -OC (0) R 11, -NR 11 C (O) R 12, -C (O) NR 11 R 12, -NR 11 R 12, hydroxy, C 1 -C 6 alkyl, Ci-C 1 alkoxy, C 6 -C aryl ? o and 5-10 membered heteroaryl; R16 is selected from the group consisting of Ci-Cß alkyl, C3-C6 alkenyl, and C3-C6 alkynyl, wherein the alkyl, alkenyl, and alkynyl moieties of the preceding R16 groups are optionally substituted with 1 to 3 substituents independently selected between the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C (O) R11, -OC (0) R11, -NR11C (O) R12, -C (O) NR11R12, -NR11R12, hydroxy, alkyl d-Ce, C6-C6 alkoxy, C6-C aryl and 5-10 membered heteroaryl, and in which at least one carbon atom of each of the foregoing R16 groups can optionally be replaced by 1 to 3 atoms or residues independently selected from the group consisting of O, N (R15) and S; each of R 17 and R 18 is independently selected from the group consisting of H, C 1 -C 10 alkyl, C 2 -C 0 alkenyl, C 2 -C 10 alkynyl, - (CH 2) m (C 6 -C 0 aryl) and - (CH2) m (5-10 membered heteroaryl), wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the foregoing groups R17 and R18 are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C (O) R11, -OC (O) R11, -NR11C (O) R12, -C (O) NR11R12, -NR11R12, hydroxy, Ci-Cß alkyl, Ci alkoxy -Cß, Ce-Cι aryl and 5-10 membered heteroaryl; each n independently represents an integer from 0 to 2; and each m independently represents an integer from 0 to
In a preferred compound of formula 1, X is -CH2NR7- or -NR7CHR6-, Z is a residue of formula b, R2 is OH, R3 is -OC (O) R14, R4 is OH and R6 is H. In another compound of formula 1, X is -NR7CHR6-; Z is a residue of formula b, R2 and R6 are taken together to form a residue of formula d, R3 is -OC (O) R14, R4 is OH and R7 is CH3. In another preferred compound of formula 1, X, Y and R3 are taken together to form a moiety of formula a, Z is a moiety of formula b, R2 is OH and R4 is OH. In another preferred compound of formula 1, X is -CH2NR7 or -NR7CHR6-, Z is a residue of formula b, R2 and R3 are taken together to form a moiety of formula c, and R4 is OH. In another preferred compound of formula 1, X, Y and R3 are taken together to form a moiety of formula a, Z is -CH (OR8) -, R2 is -OR13 and R4 is OR15. In another preferred compound of formula 1, X, Y and R3 are taken together to form a moiety of formula a, Z is -C (O) -, R2 is -OR3 and R4 is OR15. In a more preferred compound of formula 1, R1 is H; R5 is ethyl; R15 is H or methyl and R13 is a residue of the formulas e-g.
ff in which R19 is C6-C? 0 aryl or 5-10 membered heteroaryl, wherein the aryl and heteroaryl moieties of the preceding R9 groups are optionally substituted with 1 to 3 substituents selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C (O) R11, -OC (O) R12 -NR11C (O) R12, -C (O) NR11R12, -NR11R12, hydroxy, C-C-alkyl, C-alkoxy C6, aryl C6-C? 0 and heteroaryl of 5-10 members. In an even more preferred compound of formula 1, R19 is selected from the group consisting of phenyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl, -pyridyl, 3-pyridyl and 4-pyridyl. In another preferred compound of formula 1, R5 is selected from the group consisting of ethyl, isopropyl, cyclopropyl, sec-butyl, cyclobutyl, cyclopentyl, methylthioethyl and furyl.
The invention further encompasses a method for preparing a compound of formula 2
wherein R2, R5, R9, R10, and R15 are defined in this specification, which comprises contacting a compound of formula f
with a Grignard reagent for a period of time and at a temperature sufficient to form a compound of formula 2. The invention further encompasses a method for preparing a compound of formula 4
wherein R5, R9, R10, and R15 are defined in this specification, which comprises contacting a compound of formula h
with an amine oxidizing reagent for a period of time and at a temperature sufficient to form a compound of formula 4. In a preferred embodiment of the invention, the amine oxidizing reagent is selected from the group consisting of N-bromo-succinimide, N-chlorosuccinimide, iodine and bromine. The invention further encompasses a method for preparing a compound of formula 5
wherein R2, R5, R9 and R10 is defined herein, which comprises contacting a compound of formula I
with a Grignard reagent or base for a period of time and at a temperature sufficient to form a compound of formula 5. In a preferred method, the Grignard reagent is benzylmagnesium chloride. In another preferred method the base is (isopropyl-cyclohexyl-amino) -magnesium chloride. The invention further encompasses a method for forming a compound of formula 7
wherein R2 and R5 are defined herein, which comprises contacting a compound of formula
wherein R9 and R10 are defined herein, under acidic conditions for a period of time and at a temperature sufficient to form a compound of formula 7. The invention further encompasses pharmaceutical compositions comprising a compound of formula 1 or a salt thereof , pharmaceutically acceptable solvates or prodrugs and a pharmaceutically acceptable carrier. The invention further encompasses a method for treating a bacterial or protozoal infection in a mammal, fish or bird, which comprises administering to a mammal, fish or bird in need of such treatment a therapeutically effective amount of a compound of formula 1 or one of its pharmaceutically acceptable salts, solvates or prodrugs.
Definitions As used in the present context and unless otherwise indicated, the term "infection (s)" includes bacterial infection (s) and protozoan infection (s) that occur in mammals, fish or birds, as well as disorders related to bacterial infections and protozoal infections that can be treated or prevented by administering antibiotics such as the compounds of the invention. Such bacterial infections and protozoa infections and disorders related to such infections include the following: pneumonia, otitis media, sinusitis, bronchitis, tonsillitis and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus or Peptostrepcoccus spp .; pharyngitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Streptococcal groups C and G, Clostridium diptheriae, or Actinobacillus haemolyticum; respiratory tract infections, related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae or Chlamydia pneumoniae; infections of skin and soft tissue infections, abscesses and osteomyelitis, and puerperal fever uncomplicated related to infection by Staphylococcus aureus, coagulase positive staphylococci (p. eg. S. epidermis and S. hemolyticus), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcal CF groups (tiny colony streptococci), viridans streptococci, Corynebacterium minutissimum, Clostridium spp. or Bartonella henselae; watery infections of the urinary tract without complications, related to an infection by Staphylococcus saprophyllus or Enterococcus spp .; urethritis and cervicitis; and sexually transmitted diseases, related to infection by Chlamydia trachomatis, Haemophylus ducreyi, Treponema pallidum, Ureaplasma urealyticum or Neiserria gonorrheae; diseases caused by toxins, related to infection by S. aureus (food poisoning and toxic shock syndrome), or streptococci of groups A, B and C; ulcers related to a Helicobacter pylori infection; systemic febrile syndromes, related to an infection by Borrelia recurrentis; Lyme disease related to an infection by Borrelia burgdorieri; conjunctivitis, keratitis and dacryocyst related to infection by Chlamydia trachomatis, Neisseria gonorrhea, S. aureus, S. pneumoniae, S. pyogenes, H. influenzae or Listeria spp .; complex disease with disseminated Mycobacterium avium (MAC), related to an infection by Mycobacterium avium or Mycobacterium intracellulare; gastroenteritis related to an infection by Campylobacter jejunr ', intestinal protozoa related to an infection by Cryptosporidium ssp .; odontogenic infection related to a viridans streptococcal infection; persistent cough related to infection by Bordetella pertussis; gaseous grangrena related to infection by Clostridium perfringens or Bacteroides spp .; and atherosclerosis related to an infection by Helicobacter pylori or Chlamydia pneumoniae. Bacterial infections and protozoal infections and disorders related to such infections, which can be treated or prevented in animals, include the following: bovine respiratory disease, related to an infection by P. haem., P. multocida, Mycoplasma bovis or Bordetella spp .; enteric disease of cows, related to an infection by E. coli or protozoa (eg coccidia and cryptosporidia); milk cow mastitis, related to a Staph infection. aureus, Strep. uberis, Strep. agalactiae, Strep. dysgalactiae, Klebsiella spp., Corynebacterium or Enterococcus spp .; the swine respiratory disease, related to an infection by A. pleuro, P. multocida or Mycoplasma spp .; enteric swine disease related to infection by E. Coli, Lawsonia intracellularis, Salmonella or Serpulina hyodysinteriae; necrosis of cows legs, related to an infection by Fusobacterium spp .; cow metritis, related to an E. coli infection; hairy warts of cows, related to an infection by Fusobacterium necrophorum or Bacteroides nodosus; flu with purulent conjunctivitis of cows, related to an infection by Moraxella bovis; premature abortion of cows, related to a protozoa infection (eg, neosporium); urinary tract infection in dogs and cats, related to an E. coli infection; skin and soft tissue infections in dogs and cats, related to an infection by Staph, epidermidis, Staph. intermedius, coagulase neg. Staph. or P. multocida; and dental or oral infections in dogs and cats, related to an infection of Alcaligenes spp., Bacteroides spp., Clostridium spp., Enterobacter spp., Eubacterium, Peptostreptococcus, Porphyromonas or Prevotella. Other bacterial infections and protozoal infections and other disorders related to such infections, which can be treated or prevented according to the method of the present invention, are mentioned in the work of J.P. Sanford et al., "The Sanford Guide To Antimicrobial Therapy", 26th Edition (Antimicrobial Therapy, Inc., 1996). As used in the present context, and unless otherwise indicated, the term "treatment" includes treatment or prevention.
As used in the present context and unless otherwise indicated, the term "halo" means fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro, chloro and bromo. As used in the present context and unless otherwise indicated, the term "alkyl" includes saturated monovalent hydrocarbyl radicals having linear, cyclic or branched moieties, or a combination of the foregoing moieties. An alkyl group may include one or two double or triple bonds. It is understood that the cyclic alkyl groups comprise at least three carbon atoms. As used in the present context and unless otherwise indicated, the term "alkanoyl" includes -C (O) -alkyl groups in which "alkyl" is defined herein. As used in the present context and unless otherwise indicated, the term "aralkyl" includes an aryl substituted with an alkyl group or an alkyl substituted with an aryl group. As used in the present context and unless otherwise indicated, the term "aryl" includes an organic radical derived from an aromatic hydrocarbon by removal of a hydrogen, such as phenyl or naphthyl. As used in the present context and unless otherwise indicated, "Ac" denotes an acetyl group. As used in the present context and unless otherwise indicated, "Me" denotes a methyl group.
As used in the present context and unless otherwise indicated, "Et" denotes an ethyl group. As used in the present context and unless otherwise indicated, the term "heteroaryl" means an aryl group in which at least one carbon atom has been replaced by an atom selected from the group consisting of O, S and N. As used in the present context and unless otherwise indicated, the terms "heterocyclic group" and "heterocycle" include heterocyclic aromatic and non-aromatic groups, which contain one or more heteroatoms selected in each case from O , S and N. The non-aromatic heterocyclic groups include groups having only 3 atoms in their ring system, but the aromatic heterocyclic groups (ie, the heteroaryl groups) must have at least 5 atoms in their ring system. The heterocyclic groups include ring systems fused with benzo and ring systems substituted with one or more oxo moieties. An example of a 4-membered heterocyclic group is azetidinyl (azetidine derivative), an example of a 5-membered heterocyclic group is thiazolyl, and an example of a 10-membered heterocyclic group is quinolinyl. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanil, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, tiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1, 2,3 , 6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, -azabicyclo [3.1.0] hexanyl, 3-azabicyclo [4.1.0] heptanil, 3H-indolyl and quinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxaiinyl, naphthyridinyl and furopyridinyl. The preceding groups, as derived from the compounds listed above, can be linked by C or N-linked when such a binding mode is possible. For example, a pyrrole derivative group can be pyrrol-1-yl (N-linked) or pyrrole-3-yl (linked by C). As used in the present context and unless otherwise indicated, the phrase "pharmaceutically acceptable salts" includes acidic or basic group salts that may be present in the compounds of the present invention. The compounds of the present invention, which are basic in nature, are capable of forming a wide variety of salts with various inorganic and organic acids. Acids which can be used to prepare pharmaceutically acceptable acid addition salts of said basic compounds are those which form non-toxic acid addition salts, ie salts containing pharmacologically acceptable anions such as, but not limited to, hydrochloride salts, hydrobromides, hydroiodides, nitrates, sulfates, bisulphates, phosphates, acid phosphates, isonicotinates, acetates, lactates, salicylates, citrates, acid citrates, tartrates, pantothenates, bitartrates, ascorbates, succinates, maleates, gentisinates, fumarates, gluconates, glucuronates , sacchates, formates, benzoates, glutamates, methanesulfonates, ethanesulfonates benzene sulphonates, p-toluene sulphonates and pamoatos [ie 1,1'-methylene-bis- (2-hydroxy-3-naphthoates)] . The compounds of the invention that include a basic moiety, such as an amino group, can form pharmaceutically acceptable salts with various amino acids, in addition to the aforementioned acids. The compounds of the present invention, which are acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline earth metal salts and the calcium, magnesium, sodium and potassium salts in particular. In the chemical structures described herein, a wavy line indicates that the stereochemistry at the chiral center, to which the wavy line is connected, is in an R or S configuration when the wavy line is connected to a carbon atom. The compounds of the present invention have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. This invention relates to the use of all optical isomers and stereoisomers of the compounds of the present invention, and mixtures thereof, and to all pharmaceutical compositions and to all methods of treatment which may employ or contain them. The compounds of formula 1 can also exist in the form of tautomers. This invention relates to the use of all said tautomers and their mixtures. This invention also encompasses isotopically-labeled compounds of formula 1, which are identical to those of formula 1 except for the fact that one or more atoms are replaced by an atom having an atomic mass or atomic number different from the atomic mass respectively. of the atomic number that is usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 35S, 18F and 36CI , respectively. The isotopically-labeled compounds of formula 1, and their pharmaceutically acceptable salts, solvates and prodrugs, are encompassed by this invention. Certain isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful. in tissue distribution analysis of drugs and / or substrates. Tritiated (ie, with 3H) and carbon-4 (ie, with 14C) isotopes are particularly preferred for their ease of preparation and detectability. In addition, replacement with heavier isotopes, such as deuterium (i.e., with 2H) can provide certain therapeutic advantages resulting from increased metabolic stability, for example an increased in vivo half-life or reduced dosage requirements and, therefore they may be preferred in some circumstances. The isotopically-labeled compounds of the invention and their prodrugs can generally be prepared by carrying out the methods described herein, by replacing an easily available isotopically-labeled reagent for an isotopically unlabeled reagent. This invention also encompasses pharmaceutical compositions containing prodrugs of compounds of formula 1, and methods for treating bacterial or protozoal infections, comprising the administration of prodrugs of compounds of formula 1. The compounds of the invention having amino, amido, hydroxy or Free carboxylic acids can be converted into prodrugs. Prodrugs include compounds in which an amino acid residue, or a polypeptide chain of two or more (eg, two, three or four) amino acid residues, is covalently linked through an amide or ester linkage with a free amino, hydroxy or carboxylic group, of compounds of formula 1. The amino acid residues include, but are not limited to, the 20 amino acids present in nature, which are commonly designated by three-letter symbols, and also include -hydroxyproline, hydroxylysine, demosin, isodemosin, 3-methyl-histidine, norvaline, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserin, ornithine and methionine-sulfone. Additional types of prodrugs are also encompassed by the invention. For example, free carboxyl groups can be derivatized in the form of amides or alkyl esters. The amide and ester moieties may incorporate groups including, but not limited to, functionalities of ether, amine, and carboxylic acid. Free hydroxy groups may be derivatized using groups including, but not limited to, hemisuccinates, phosphate esters, dimethylamino-acetates and phosphoryloxy-methyloxy-carbonyls, as noted in the citation of D. Fleisher, R. Bong, BH Stewart, Advanced Drug Delivery Reviews 19: 115 (1996). Prodrugs with hydroxy and amino group carbamates are also encompassed by the invention, as are prodrugs with carbonates and sulfate esters of hydroxy groups. The derivatization of hydroxy groups in the form of (acyloxy) methyl-y (acyloxy) ethyl esters, in which the acyl group can be an alkyl ester, optionally substituted with groups including but not limited to ether, amine functionalities and carboxylic acid, or in which the acyl group is an ester of an amino acid such as those described above, are also encompassed by the invention. Prodrugs of this type are described in the R.P. Robinson et al., J. Medicinal Chemistry 39:10 (1996).
DETAILED DESCRIPTION OF THE INVENTION
This invention relates to new macrolide compounds, to methods for preparing them, and to pharmaceutical compositions comprising them. The invention further relates to methods for treating or preventing bacterial and protozoal infections in mammals (eg, humans), fish and birds, as well as methods for treating or preventing other diseases or conditions such as, but not limited to, cancer, atherosclerosis and disorders of the gastric modality. Specific compounds of the invention have the formula 2, and are listed in table 1:
TABLE 1
The information on mass spectra (MS) and yields, which are given in Table 1, are related to the preparation of the compounds 2 (a) -2 (n), as described below in the examples. The compounds of formula 2 can be prepared according to the method shown in scheme 1:
SCHEME 1
According to scheme 1, the compounds of formula 2 can be prepared from compounds of formula e, the synthesis of which is described by the patents of E.U.A. Nos. 4,474,768 and 4,517,359, both of which are incorporated herein by reference. According to this method, a carbonate compound of formula f is prepared from the compound e using the synthesis conditions that are known to those skilled in the art. Preferred conditions comprise the use of ethylene carbonate and a base such as potassium carbonate in a solvent such as ethyl acetate. Then, carbonate f can be reacted with a Grignard reagent to provide compound 2. Other compounds of the invention are those of formula 3, of which specific examples are listed in Table 2:
TABLE 2
As above, the information on MS and yields given in table 2 are given in relation to the preparation of compounds 3 (a) -3 (m), as described below in the examples. The compounds of formula 3 can be prepared according to the method shown in scheme 2:
SCHEME 2
Amine
According to scheme 2, the compounds of formula 3 can be prepared easily from compounds of formula g, which can be prepared according to scheme 1. In particular, compounds of formula 3 can be prepared by dissolving the compounds of formula g in a liquid amine and subsequently stirring the resulting mixture for a sufficient period of time and at a sufficient temperature (eg, approximately for 2 days at room temperature). Alternatively, the compounds of formula g and a liquid or solid amine can be dissolved in a solvent, which can then be stirred for a sufficient period of time and at a temperature sufficient to provide compounds of formula 3. Still other compounds of the invention are of formula 4, of which specific examples are listed in table 3:
TABLE 3
In which the information on MS and yields given in table 3 are related to the preparation of the compounds 4 (a) -4 (b), as described below in the examples. The compounds of formula 4 can be prepared according to the method shown in scheme 3:
SCHEME 3
Amine oxidizing agent
According to scheme 3, the compounds of formula 4 can be prepared easily from compounds of formula h, which in turn can be prepared according to the method of scheme 1. In particular, the compounds of formula 4 are they can be prepared by reacting compounds of formula h with an amine oxidizing reagent in an appropriate solvent such as, but not limited to, ethyl acetate and tetrahydrofuran (THF). Suitable amine oxidizing agents include, but are not limited to, N-bromo-succinimide (NBS), N-chlorosuccinimide (NCS), iodine and bromine. Other examples of compounds of the invention and of preferred methods for their synthesis are provided in the examples presented below. The compounds of the present invention may have asymmetric carbon atoms, and the diastereoisomeric mixtures thereof, can be separated into their individual diastereomers on the basis of their physical and chemical differences by methods known to those skilled in the art, for example by chromatography or fractional crystallization. The enantiomers can be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (eg an alcohol), separation of the diastereomers and conversion (eg by hydrolysis) of the individual diastereoisomers in the corresponding pure enantiomers. All such isomers, including mixtures of diastereomers and pure enantiomers, are considered as a part of the invention. The compounds of the invention (ie, compounds of formula 1) which are basic in nature, are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts should be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the invention from the reaction mixture in the form of a pharmaceutically unacceptable salt and then simply convert the latter back into the compound in free base form by treatment with an alkaline reagent and subsequently converting the latter free base into a pharmaceutically acceptable acid addition salt. The acid addition salts of the basic compounds of this invention are readily prepared by treating a compound of basic character with a substantially equivalent amount of the chosen inorganic or organic acid in an aqueous solvent medium or in an appropriate organic solvent, such as methanol or ethanol. After careful evaporation of the solvent, the desired solid salt is easily obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding an appropriate inorganic or organic acid to the solution. The compounds of the invention, which are acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline earth metal salts and, particularly, the sodium and potassium salts. These salts can be prepared by conventional techniques. The chemical bases that are used as reagents for preparing the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the invention. Non-toxic base salts include those which are derived from pharmacologically acceptable cations such as, but not limited to, sodium, potassium, calcium and magnesium. These salts can be prepared by treatment of the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations and then by evaporation of the resulting solution to dryness, preferably under reduced pressure. Alternatively, these can be prepared by mixing together solutions in lower alkanols of the acidic compounds and the desired alkali metal alkoxide, and then evaporating the resulting solution to dryness, in the same manner as above. In either case, stoichiometric amounts of reagents are preferably employed in order to ensure the completion of the reaction and maximum yield of the desired final product. The activity of the compounds of the present invention against bacterial and protozoan pathogens is demonstrated by the ability of the compounds to inhibit the growth of defined strains of human pathogens (analysis I) or animals (analyzes II and III).
Analysis I Analysis I, described below, employs a conventional methodology and interpretation criteria and is designed to provide guidelines for chemical modifications that can lead to compounds that avoid defined mechanisms of resistance to macrolides. In analysis I, a panel of bacterial strains including a diversity of target pathogenic species, including those representative of mechanisms of resistance to macrolides that have been characterized, is assembled. The use of this panel makes it possible to determine the relationship of the chemical structure and the activity with respect to the power, the spectrum of activity and structural elements or modifications that may be necessary to avoid the mechanisms of resistance. The bacterial pathogens that the screening panel comprises are shown below in Table 4. In many cases, both the macrolide-susceptible parent strain and the macrolide-resistant strain derived therefrom are available to provide a more accurate investigation of the capacity of the macrolide. the compounds to avoid the resistance mechanism. Strains containing the gene with the designation ermA / ermB / ermC are resistant to antibiotics macrolides, lincosamides and streptogramin B due to modifications (by methylation) of 23S rRNA molecules by an Erm-methylase that generally prevents the fixation of the three structural classes. Two types of macrolide efflux have been described; msrA encodes a component of an efflux system in staphylococci, which prevents the entry of macrolides and streptogramins, while mefA / E encodes a transmembrane protein that manifests effluir only macrolides. Deactivation of macrolide antibiotics can occur and this can be mediated either by phosphorylation of the 2'-hydroxyl group (mph) or by dissociation of the macrocyclic lactone (esterase). The strains can be characterized using a conventional polymerase chain reaction (PCR) technology and / or by sequencing the resistance determinant. The use of a PCR technology in this application is described in the work of J. Sutcliffe et al., "Detection Of Erythromycin-Resistant Determinants by PCR", Antimicrobial Agents and Chemotherapy, 40 (11): 2562-2666 (1996). The antibacterial analysis is performed in microtitre trays and is interpreted according to the guidelines of the work Performance Standards for Antimicrobial Disk Susceptibilitv Tests-Sixth Edition; Approved Standard, published by the National Committee for Clinical Laboratory Standards (NCCLS); The minimum inhibitory concentration (MIC) is used to compare the strains. Acr AB or similar to acr AB indicates that there is an intrinsic multiple drug efflux pump in the strain. The compounds are initially dissolved in dimethyl sulfoxide (DMSO) as original solutions of 40 mg / ml.
TABLE 4
Analysis II, as described below, is used to assay for activity against Pasteurella multocida and analysis III is used to test for activity against Pasteurella haemolytica.
Analysis II This analysis is based on the dilution method with liquids in the microliter format. A single colony of P. multocida (strain 59A067) is inoculated into 5 ml of brain and heart infusion broth (BHI, from Brain Heart Infusion). The test compounds are prepared by solubilizing 1 mg of the compound in 125 ml of dimethyl sulfoxide (DMSO). Dilutions of the test compound are prepared using an inoculated BHI broth. The concentrations used of the test compound range from 200 mg / ml to 0.098 mg / ml by serial dilutions of double ratio. The BHI inoculated with P. multocida is diluted with uninoculated BHI broth to prepare a suspension of 104 cells per 200 ml. The cell suspensions in BHI are mixed with respective serial dilutions of the test compound and incubated at 37 ° C for 18 hours. The minimum inhibitory concentration (MIC) is equal to the concentration of the compound exhibiting a 100% inhibition of growth of P. multocida as determined by comparison with an uninoculated control.
Analysis III The analysis is based on the dilution method of agar using a
Replicator of Steers. Two to five colonies isolated from an agar plate are inoculated in a BHI broth and incubated overnight at 37 ° C with shaking (200 rpm). The next morning, 300 ml of fully grown P. haemolytica preculture are inoculated in 3 ml of fresh BHI broth and incubated at 37 ° C with shaking (200 rpm). The appropriate amounts of the test compounds are dissolved in ethanol and a series of double-ratio serial dilutions are prepared. Two ml of the respective serial dilution are mixed with 18 ml of molten BHI agar and solidified. When the inoculated P haemolytica culture reaches a standard density according to McFarland of 0.5, approximately 5 ml of P. haemolytica culture are inoculated on BHI agar plates containing the various concentrations of the test compound using a Steers Replicator and incubated for 18 hours at 37 ° C. The initial concentrations of the test compound range from about 100 to about 200 mg / ml. The MIC is equal to the concentration of the test compound exhibiting a 100% inhibition of growth of P. haemolytica as determined by comparison with an uninoculated control. The in vivo activity of the compounds of the invention can be determined by conventional animal protection studies that are also known to those skilled in the art, usually carried out in mice. Mice are assigned to cages (10 per cage) after arrival, and allowed to: acclimatize for a minimum of 48 hours before being used. The animals are inoculated with 0.5 ml of a bacterial suspension of 3 x 103 CFU / ml (P. multocida strain 59A006) intraperitoneally. Each experiment has at least 3 non-medicated control groups including one infected with a 0.1X stimulation dose and two infected with a 1X stimulation dose; a group of 10X stimulation data can also be used. Generally, all mice in a given study can be stimulated for about 30 to about 90 minutes, especially if a repeating syringe (such as a Comawallá syringe) is used to administer the stimulus. Thirty minutes after the stimulation has begun, the first compound treatment is administered. It may be necessary for a second person to begin dosing the compound if all the animals have not been stimulated at the end of 30 minutes. The routes of administration are subcutaneous or oral doses. Subcutaneous doses are administered to the loose skin on the back of the neck while oral doses are administered by means of a feeding needle. In both cases, a volume of 0.2 ml per mouse is used. The compounds are administered 30 minutes, 4 hours and 24 hours after the stimulus. A control compound of known efficacy administered by the same route is included in each assay. The animals are observed daily, and the number of survivors in each group is recorded. Surveillance of the P. multocida model continues for 96 hours (four days) after stimulation. DP5o is a calculated dose with which the compound tested protects 50% of a group of mice with respect to a mortality due to bacterial infection that would be lethal in the absence of drug treatment. The compounds of the invention and their pharmaceutically acceptable salts, solvates and prodrugs (herein also referred to as "active compounds of this invention") can be administered alone or in combination with pharmaceutically acceptable carriers, in single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining the active compounds of this invention can then be administered easily in a variety of dosage forms, such as, but not limited to, tablets, powders, rhombic pills, syrups and injectable solutions. These pharmaceutical compositions may contain, if desired, additional ingredients such as, but not limited to, flavors, flavors, binders and excipients. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be used together with various disintegrating agents such as starch, methylcellulose, alginic acid and a hundred complex silicates, together with binding agents such as poly (vinyl pyrrolidone), sucrose, gelatin and gum arabic. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and ta 'o are often useful for tablet compression purposes. Solid compositions of a similar type can also be used as fillings in capsules filled with hard and soft gelatin. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient in these formulations may be combined with various sweetening or flavoring agents, coloring materials or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol and combinations thereof. For parenteral administration, solutions containing an active compound of this invention, or a pharmaceutically acceptable salt thereof, in sesame or peanut oil, aqueous propylene glycol or in a sterile aqueous solution can be employed. Said aqueous solutions should be appropriately buffered if necessary and the liquid diluent should first be made isotonic with sufficient amount of saline or glucose. These particular aqueous solutions are especially suitable for administration intravenously, intramuscularly, subcutaneously and intraperitoneally. The sterile aqueous media used are readily available from all of them by conventional techniques that are known to those skilled in the art. To perform the methods of this invention, an effective dose of an active compound of this invention is administered to a susceptible or infected animal (including mammals, fish and birds) by parenteral (iv, im or sc), oral or rectal routes, or locally as a topical application to the skin and / or mucous membranes. The route of administration will depend on the mammal, fish or bird that is being treated. The effective dose will vary with the severity of the disease, and with the age, weight and condition of the animal. However, the daily dose will usually fluctuate between about 0.25 and about 150 mg / kg of body weight of the patient being treated, preferably from about 0.25 to about 25 mg / kg. The examples given below illustrate specific embodiments of the invention, but the invention is not limited in scope to the examples specifically exemplified.
EXAMPLES 1-12 Synthesis of compounds 2 (a) -2 (l)
Compounds 2 (a) -2 (l), whose structures are presented in Table 1, were prepared as shown in scheme 1 from the azalide derivative e, the synthesis of which has been described by the patents of E.U.A. Nos. 4,474,768 and 4,517,359. The derivative e (10 g) was dissolved in EtOAc (150 ml), followed by the addition of ethylene carbonate (10 eq.) And K2CO3 (2 eq.). The resulting solution was stirred at 75 ° C for one to five days, and the reaction was monitored by thin TLC (Thin Layer Chromatography) chromatography. After the reaction was complete, the reaction mixture was cooled to room temperature, and diluted with EtOAc (250 ml) and with water (100 ml). The organic strain was washed with water (4 x 100 ml), with brine (2 x 100 ml) and dried (Na2SO). Then the solvent was removed in vacuo to give the crude product, which was purified either by flash chromatography using 3% MeOH and 0.5% ammonia in CH2Cl2 or by recrystallization from CH3CN to give compound f (shown in the scheme 1), typically with a yield greater than about 80%. The azalide carbonate f (0.5 mmol - 5 mmol) was dissolved in CH2Cl2 (10 ml -100 ml) and cooled to -78 ° C. The Grignard reagent (eg, vinylmagnesium bromide) (6-10 equivalents) was then added slowly at this temperature and the reaction was monitored by TLC. If there was no reaction at this temperature and the reaction was monitored by TLC. If there was no reaction at this temperature, the reaction mixture was then heated to a higher temperature. After the reaction was complete, usually over a period of time between 15 minutes and 4 hours, it was quenched with a saturated solution of NH CI (25 ml -250 ml). The aqueous layer was extracted with CH2Cl2 (100 ml-500 ml) and the organic layer was then washed with a saturated solution of NaHCO3 (25 ml-100 ml) and with brine (25 ml-100 ml). The organic layer was dried with Na 2 SO 4 and the solvent was removed in vacuo to give the crude product of formula 2, which was purified by flash chromatography using 1-5% MeOH and 0.5% ammonia in CH 2 Cl 2.
EXAMPLE 13 Synthesis of compound 2 (m)
The azalide carbonate f, shown in scheme 1 and prepared according to examples 1-12, in which R7 is methyl (3.00 g, 3.87 mmol) was dissolved in a mixture of ethylene glycol dimethyl ether (75 ml) ) and NNN'N'-tetramethyl-ethylene-diamine (30 ml). The reaction solution was cooled to -78 ° C, and then 1 M vinylmagnesium bromide in THF (31 ml, 31 mmol) was slowly added at this temperature. After the stirring had been continued for 2 hours at -78 ° C, the reaction was quenched with a saturated solution of NH CI (100 ml). The aqueous layer was extracted with EtOAc (400 ml) and the organic layer was washed with a saturated solution of NaHCO3 (50 ml) and with brine (50 ml). Then the organic layer was dried with Na2SO and the solvent was removed in vacuo to give the crude product, which was purified by flash chromatography using 5% MeOH and 0.5% ammonia in CH2Cl2 (1.43 g, 46%).
EXAMPLE 14 Synthesis of compound 2 (n)
The azalide carbonate f, shown in scheme 1 and prepared according to examples 1-12, in which R7 is methyl (3.00 g, 3.87 mmol) was dissolved in a mixture of ethylene glycol dimethyl ether (75 ml) ) and N, N, N'N'-tetramethyl-ethylene-diamine (30 ml). The reaction solution was cooled to -40 ° C, and then 1 M methylmagnesium bromide in ether solution (12.9 mL, 38.7 mmol) was added slowly at this temperature. After the stirring had been continued for 2 hours at -40 ° C, the reaction was quenched with a saturated solution of NH CI (100 ml). The aqueous layer was extracted with EtOAc (400 ml) and the organic layer was washed with a saturated solution of NaHCO3 (50 ml) and with brine (50 ml). The organic layer was then dried with Na2SO and the solvent was removed in vacuo to give the crude product, which was purified by flash chromatography using 5% MeOH and 0.5% ammonia in CH2Cl2 (1.08 g, 40%).
EXAMPLE 15-26 Synthesis of compounds 3 (a) -3 (l)
The compounds 3 (a) -3 (l), whose structures are presented in Table 2, were prepared as shown in scheme 2 from the azalide derivative g, which can be prepared according to scheme 1 and Example 13. The azaiide derivative g (50-200 mg) was dissolved in 0.2-1.0 ml of the appropriate amine (e.g., t-butyl-amine) and the reaction mixture was stirred at room temperature for 2 hours. days. The reaction mixture was then diluted with CH2Cl2 (200 ml) and washed with water (6 x 25 ml) and brine (25 ml). Then the organic layer was dried with Na 2 SO 4 and the solvent was removed in vacuo to give the crude product, which was purified by flash chromatography using 3-5% 2 M ammonia in a MeOH solution in CH 2 Cl 2.
EXAMPLE 27 Synthesis of compound 3 (m)
The azalide derivative g shown in scheme 2, wherein R7 is methyl (188 mg, 0.234 mmol) and tryptamine (129 mg, 0.802 mmol) were dissolved in THF (2 ml), and the reaction mixture was stirred at the room temperature for 25 hours. Then the reaction mixture was diluted with CH2Cl2 (200 ml) and washed with a 0.1 M sodium phosphate buffer pH 7 (3 x 25 ml). Then the organic layer was washed with brine (25 ml), and dried with Na2SO4. The solvent was evaporated in vacuo to give the crude product, which was purified by flash chromatography using 5% 2 M ammonia in a MeOH solution in CH 2 Cl 2 to give the title compound (35.6 mg, 16%).
EXAMPLE 28 Synthesis of compound 4 (a)
The derivative of azalide h, shown in scheme 3 and prepared according to scheme 1 and examples 1-12 above, in which R15 is methyl (0.528 g, 0.667 mmol) was dissolved in THF (50 ml) and the solution The resultant was cooled to 0 ° C. Under stirring conditions, NBS (0.119 g, 0.670 mmol) was added and stirring was continued at 0 ° C for 0.5 hours. EtOAc (250 ml) was added and the organic layer was washed with a 0.1 N NaOH solution (50 ml) and with brine (50 ml). The organic layer was then dried with Na2SO4 and the solvent was removed in vacuo to give the crude product, which was purified by flash chromatography using 3% 2M ammonia in MeOH solution in CH2Cl2 to give the title compound (275 mg, 52%).
EXAMPLE 29 Synthesis of compound 4 (b)
The azalide derivative h, shown in scheme 3, in which R15 is vinyl (85.1 mg, 0.106 mmol) was dissolved in THF (10 ml) and the resulting solution was cooled to 0 ° C. Under stirring conditions, NBS (19.7 mg, 0.111 mmol) was added, and stirring was continued at 0 ° C for 2 hours. EtOAc (100 ml) was added and the organic layer was washed with a 0.3 N NaOH solution (10 ml) and with brine (10 ml). Then the organic layer was dried with Na2SO4 and the solvent was removed in vacuo to give the crude product. The product was purified by flash chromatography using first 7% 2 M ammonia in a MeOH solution in CH 2 Cl 2 and then 7% 2 M ammonia in a MeOH solution in EtOAc (28.4 mg, 33%).
EXAMPLE 30 Synthesis of compound 5 (a
Compound 5 (a), wherein R2 is OH, R5 is ethyl, R9 is H, and R) is OH, was prepared according to scheme 4:
SCHEME 4
BnMgCI CH2Cl2
According to scheme 4, compounds of formula 5 can be prepared by reacting a compound of formula i with a Grignard reagent such as benzyl magnesium chloride or with a base such as (isopropyl-cyclohexyl-amino) chloride. magnesium in a solvent such as dichloromethane at an appropriate temperature. In particular, the azalide carbonate i wherein R 2 is OH, R 5 is ethyl, R 9 is H and R 0 is OH, the synthesis of which is described by the provisional patent application in E.U.A. 60/097075, which is incorporated herein by reference, (2.28 g, 3 mmol) was dissolved in CH 2 Cl 2, under stirring conditions, benzyl magnesium chloride (15.0 mL, 30 mmol) was added over 2 minutes. After the resulting reaction mixture had been stirred at room temperature for 1 hour, it was quenched with a saturated solution of NH CI (50 ml). The product was extracted with CH2Cl2 (300 ml). Then the organic layer was washed with brine (50 ml), dried with Na 2 SO 4, and the solvent was removed in vacuo to give the crude product which was purified by flash chromatography using 1.25% MeOH, 0.5% ammonia in CH 2 Cl 2 to give the title compound (851 mg, 40%, MS: 717.2).
EXAMPLE 31 Synthesis of compound 6 (a) Compound 6 (a) was prepared according to scheme 5: SCHEME 5
BnMgCI CH CI
Í6a) According to scheme 5, the compounds of formula 6 (a) can be prepared by reacting compounds of formula i with a Grignard reagent such as vinyl magnesium bromide in a solvent such as dichloromethane at a temperature appropriate Appropriate reaction times are typically from about 0.5 hours to about 24 hours. In particular, the azalide carbonate i (3.00 g, 3.95 mmol) was dissolved in CH2Cl2 (100 ml) and cooled to -78 ° C. Under stirring conditions, vinyl magnesium bromide was added and stirring was continued at -78 ° C for 1.5 hours. The reaction was then quenched with a saturated solution of NH 4 Cl (50 ml) and the reaction mixture was warmed to room temperature. The aqueous layer was extracted with CH2Cl2 (200 ml) and the combined organic layers were washed with a saturated solution of NaHCO3 (50 ml) and brine (50 ml). The organic layer was dried with Na 2 SO 4, and the solvent was removed in vacuo to give the crude product which was purified by flash chromatography using •% MeOH, 0.5% ammonia in CH 2 Cl 2 to give the compound of Example 5 as the product main (27%) and the compound of Example 31 as the secondary product (40.0 mg, 1.4%, MS: 717.2).
EXAMPLE 32 Synthesis of compound 7 (aT)
As shown below in scheme 6, acidic conditions can be used to remove the cladinose residue of the compounds of formula 5, thereby forming compounds of formula 7:
SCHEME 6
acid
In this example, compound 7 (a), which is of formula 7, wherein R 2 is OH and R 5 is ethyl, was prepared by adding acetyl chloride (5.95 μl) to methanol (2 ml) in a round-bottomed flask of 25 ml capacity. The resulting solution was stirred at room temperature for 5 minutes. The azalide derivative 5 (a) (20.0 mg) was added to the solution, and the reaction mixture was stirred at room temperature for 48 hours. The MeOH was then removed in vacuo, the residue was dissolved in methylene chloride (20 ml) and in a saturated solution of sodium hydrogen carbonate (10 ml). After separation, the organic layer was washed with brine (10 ml) and dried with MgSO 4. The solvent was then removed in vacuo to give the crude product, which was purified by flash chromatography using 5% MeOH and 1% ammonia in methylene chloride to give the title compound (14 mg, 89%, MS: 559.2).
EXAMPLE 33 Synthesis of compound 8 'a)
As shown below in scheme 7, compounds such as 5 (a) can be converted to compounds such as 8 (a) using methods such as those described in WO 98/09978, which is incorporated herein by reference. reference.
SCHEME 7
5th]
SCHEME 7 (continued)
0)
AcCl, MeOH 15
twenty
SCHEME 7 (continued)
0) (1) Benzoic anhydride E jN, CH2CI (2) EDC, DMSO, CH2CI2
m
(1) 3-bromoquinoline Pd (OAc) 2, P (-o-tolyl) 3 CH 3 CN (2) MeOH 15
8 (a) Scheme 7 shows a specific embodiment of a general method encompassed by the invention for preparing compounds such as that of formula 8 (a). As will be recognized by those skilled in the art, the specific order of operations, and the specific reactants and reaction conditions shown in Scheme 7 can be varied. For example, hydroxyl groups of sugars can be protected, and forming the 6-O-alkenyl derivative, before dissociating the cladinose residue. However, in the preferred embodiment of the general method of synthesis of the invention shown in scheme 7. The 2'- and 4"-hydroxy groups of a compound such as that of the formula 5 (a) are first protected by reaction with an appropriate hydroxy protecting reagent such as TMS-CI, acetic anhydride or benzoic anhydride, in an aprotic solvent such as dichloromethane to provide the compound I. The 6-hydroxy group of compound i is then alkylated by reaction with an agent alkylator in the presence of a base, followed by removal of the 2'- and 4"-hydroxy protecting groups to give compound K. Alkylating agents include, but are not limited to, alkyl chlorides, bromides or iodides or alkyl sulfonates. Alkylating agents include, but are not limited to, allyl bromide, propargyl bromide, benzyl bromide, and allyl O-tosylate Examples of solvents include, but are not limited to, aprotic solvents such as DMSO, DMF, THF, and diethyl ether. ether and mixtures thereof Examples of a base that can be used to provide a compound of formula k include, but are not limited to, potassium hydroxide, potassium isopropoxide and potassium tert-butoxide. and 4"-hydroxy is carried out by classical methods known to those skilled in the art. Compound k is converted to compound I by removal of the cladinose residue. The appropriate reaction conditions include those described above in Example 31. The 2 'hydroxyl group of compound I is then protected by reaction with benzoic anhydride as in step 1. Depending on the compound, this reaction time may vary between about 1 hour and about 2 days. The 3-hydroxyl group of compound I is then oxidized to provide the ketone of compound m using a modified Swern oxidation procedure. Suitable oxidizing agents include, but are not limited to, carbodiimide-dimethyl sulfoxide and N- (chlorosuccinimide) -dimethyl sulphide. In the final operation of the general method exemplified by scheme 7, compound m is converted to the 6-O- (substituted alkenyl) derivative (eg, of formula 8 (a)) by reaction with an aryl halide , a substituted aryl halide, a heteroaryl halide or a substituted heteroaryl halide, under the conditions of Heck, with Pd (ll) or Pd (O), phosphine, and an amine or organic base. See, p. ex. Organic Reactions, 27: 345-390 (1982). The 2'-hydroxyl protecting group is then removed by conventional methods to give the compound of formula 8 (a). In a specific application of the synthesis of scheme 7, the azalide derivative 5 (a) (1 mmol) is dissolved in methylene chloride, followed by the addition of triethylamine (2.2 mmol). The resulting reaction mixture is cooled in an ice-water bath, TMS-CI (2.2 eq.) Is added slowly, and the reaction mixture is stirred at room temperature overnight. After the reaction is complete, the reaction mixture is concentrated in vacuo and the residue is dissolved in methylene chloride. The organic layer is washed with water, with brine and dried with MgSO 4. The solvent is evaporated in vacuo to give the azalide derivative i. To a solution at 0 ° C of compound i (1 mmol) in 5 ml of DMSO and 5 ml of THF is added freshly distilled allyl bromide (1.1 mmoles). After about 5 minutes, a solution of potassium tert-butoxide (1 M, 1.1 ml) in 5 ml of DMSO and 5 ml of THF is added dropwise over 4 hours. The reaction mixture is taken up in ethyl acetate (200 ml) and washed with water and brine. The organic solvent is removed in vacuo to give the allyl derivative. This allyl derivative (1 mmol) is dissolved in 10 ml of CH3CN and 5 ml of H2O, followed by the addition of AcOH (5 eq.), And the resulting solution is stirred at room temperature for 4 to 24 hours. After the reaction is complete, the reaction mixture is diluted with toluene (100 ml) and concentrated in vacuo, and the crude product is purified by flash chromatography using 3% MeOH and 0.5% ammonia in CH 2 Cl 2 for give the derivative of azalide k. AcCl (3 mmol) is added to MeOH (30 mL) and the resulting solution is stirred at room temperature for 15 minutes. After which the reaction solution had cooled to 0 ° C, compound k (1 mmol) is added and the reaction mixture is stirred at room temperature for 48 hours. The solvent is removed in vacuo and the residue is dissolved in CH2Cl2. After washing with a saturated solution of NaHCO3 and with brine and drying with Na2SO4, the organic solvent is removed in vacuo to the crude product, which is purified by flash chromatography using 3% MeOH and 0.5% ammonia in CH 2 Cl 2 to provide the azalide derivative I. To a solution of compound I (1 mmol ) in CH 2 Cl 2 (10 mL) is added benzoic anhydride (1 mmol) and Et 3 N (1 mmol), and the resulting reaction mixture is stirred at room temperature for 1 to 2 days. The reaction mixture is diluted with CH2Cl2 and washed with a saturated solution of NaHCO3 and with brine, and dried with Na2SO4, and the organic solvent is removed under vacuum to give the benzoylated derivative. This is then dissolved in 20 ml of CH2Cl2, followed by the addition of DMSO (10 mmol). The reaction mixture is then cooled to 0 ° C and EDC (4 mmol) is added. The reaction solution is stirred at room temperature overnight. After the reaction is complete, the reaction mixture is diluted with 100 ml of CH 2 Cl 2, washed with a saturated solution of NaHCO 3 and with brine, and dried with Na 2 SO 4. The organic solvent is removed in vacuo to give the crude product, which is purified by chromatography on silica gel using 30% acetone in hexanes to provide the azalide derivative m. A mixture of compound m (0.25 mmol), palladium (II) acetate (0.2 eq.), Tri-o-tolyl-phosphine (0.4 eq.), 3-bromo-quinoline (2 eq.) And triethylamine ( 2 eq.) In 2 ml of acetonitrile is cooled to -78 ° C, degassed, and hermetically sealed. The reaction mixture is then heated at 50 ° C for 2 hours and stirred at 80 ° C for 16 hours. The reaction mixture is taken up in CH 2 Cl 2, washed with a saturated solution of NaHCO 3 and with brine, and dried with Na 2 SO 4, the organic solvent is removed in vacuo to give the crude product, which is purified by chromatography with silica gel using 2% MeOH in CH2Cl2. This purified product is then dissolved in MeOH and the resulting solution is stirred at reflux for 6 to 24 hours. The solvent is then removed in vacuo and the crude product is purified by flash chromatography using 2% MeOH and 0.5% ammonia in CH 2 Cl 2 to give compound 8 (a).
Claims (18)
- the ones the R3
- Z is selected from the group consisting of -C (O) -, -CH (-OR8) -, and the rest of formula b
- R1 is H or a hydroxy protecting group; R2 is -OR13, or R2 and R3 are taken together to form the remainder of formula c or if X is -NR7CHR6-, R2 and R6 can be taken together to form the remainder of formula d
- R3 is -OC (0) R14, or R3, X and Y are taken together to form the rest of formula a, or R3 and R2 are taken together to form the remainder of formula c; R4 is -OR15; R5 is a C2-C8 alkyl group, C2-Cs alkenyl, C2-C8 alkynyl, C2-C8 alkoxyalkyl or C2-C8 alkylthioalkyl branched alpha, optionally substituted with at least one hydroxyl group, a C2-C5 alkyl group branched at alpha, linked to a Cs-Cs cycloalkyl group; a C3-C8 cycloalkyl or cycloalkenyl group optionally substituted with at least one moiety selected from the group consisting of methyl, hydroxy, halo and C4 alkyl groups; or a saturated, or fully or partially unsaturated, heterocycle of 3-6 members, comprising at least one oxygen or sulfur atom and optionally substituted with one or more C1-C4 alkyl groups or halogen atoms; R6 is H, or if X is -NR7CHR6-, R6 and R2 can be taken together to form the remainder of formula d; R7 is selected from the group consisting of H, C1-C10 alkyl, C2-C10 alkenyl, C2-C0 alkynyl, - (CH2) m (aryl Ce-Cio) and 5-10 members), wherein the residues of alkyl, alkenyl, aryl, heteroaryl and alkynyl of the preceding R7 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C (O) R11, -OC (O) R 11, -NR 11 C (O) R 12, -C (O) NR 11 R 12, -NR 11 R 12, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 6 -C 10 aryl and 5-10 membered heteroaryl; R 8 is selected from the group consisting of H, C 1 -C 10 alkyl, C 2 -C 0 alkenyl > C 2 -C 0 alkynyl, -C (O) R 17, -C (O) NR 7 R 18, - (CH 2) m (C 1 -C aryl) and - (CH 2) m (5-10 membered heteroaryl), wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the preceding R8 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C (O) R11, -OC (O) R11, -R11C (O) R12, -C (O) NR11R12, -NR11R12, hydroxy, C? -C6 alkyl, C? -C6 alkoxy, C6-C? 0 aryl and 5-10 heteroaryl members; R9 is hydroxy; R10 is selected from the group consisting of H, C1-C10 alkyl, C2-C? Alkenyl, C2-C alqu alkynyl, cyano, -CH2S (O) nR11, -CH2OR11, -CH2NR11R12, - (CH2) m (C6-C8 aryl) and - (CH2) m (5-10 membered heteroaryl), wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the preceding R10 groups are optionally substituted with 1 to 3 substituents independently from each other the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C (O) R11, -OC (O) R11, NR11C (O) R12, -C (O) NR11R12, -NR11R12, hydroxy, C alkyl? -C6, C6-C6 alkoxy, C6-C6 aryl and 5-10 membered heteroaryl; each R 11 and R 12 is independently selected from the group consisting of H, C C β alkyl, C 2 -C 6 alkenyl, (CH 2) m (C 6 -C 0 aryl), (CH 2) m (5-10 membered heteroaryl) and C2-C? alkynyl, wherein the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the foregoing groups R11 and R12 are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, CrCß alkyl and C6-C6 alkoxy; R13 s selected from the group consisting of H, C1-C10 alkyl, C2-C0 alkenyl, C2-C10 alkynyl, -R16 (Ce-Cio aryl), and -R16 (5-10 membered heteroaryl), in that the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the preceding R13 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C (O) R1 ? -OC (O) R11, -NR11C (O) R12, -C (O) NR1 R12, -NR11R12, hydroxy, C? -C6 alkyl, Ci-C? Alkoxy, C? -Ci aryl and heteroaryl? 10 members; R 14 is selected from the group consisting of C 1 -C 10 alkyl, C 2 -C 0 alkenyl, C 2 -C 10 alkynyl, - (CH 2) m (C 6 -C 0 aryl) and - (CH 2) m (5- heteroaryl) 10 members), in which the alkyl, alkenyl, aryl, heteroaryl and alkynyl moieties of the preceding R14 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro trifluoromethyl, azido, -C (O) R11, -OC (O) R11, -NR11C (O) R12, -C (O) NR11R12, NR11R12, hydroxy, CrC6 alkyl, CrCβ alkoxy, Ce-Cι aryl and 5-10 membered heteroaryl; each R 15 is independently selected from the group consisting of H, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 8 alkynyl, - (CH 2) m (C 6 -C 0 aryl) and - (CH 2) m ( 5-10 membered heteroaryl), wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the preceding R15 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl , azido, -C (O) R11, -OC (O) R11, -NR11C (O) R12, -C (O) NR1 R12, -NR11R12, hydroxy, CrC6 alkyl, CrC6 alkoxy, C6-C6 aryl, and 5-10 membered heteroaryl; R16 is selected from the group consisting of CrCß alkyl, C3-C6 alkenyl, and C3-C6 alkynyl, wherein the alkyl, aikenyl, and alkynyl moieties of the preceding R16 groups are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, cyano, nitro, trifluoromethyl, azido, -C (0) R11, -OC (O) R1 \ -NR11C (O) R12, -C (O) NR11R12, -NR11R12, hydroxy, CrC6 alkyl, alkoxy CrC6, Ce-Cryl aryl and 5-10 membered heteroaryl, and in which at least one carbon atom of each of the foregoing R16 groups may optionally be replaced by 1 to 3 atoms or residues independently selected from the group consisting of O, N (R15) and S; each of R 17 and R 18 is independently selected from the group consisting of H, CrCl 3 alkyl, C 2 -C 0 alkenyl, C 2 -C 0 alkynyl, - (CH 2) m (C 6 -C 0 aryl) and - ( CH2) m (5-10 membered heteroaryl), wherein the alkyl, alkenyl, alkynyl, aryl and heteroaryl moieties of the foregoing groups R17 and R18 are optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo , cyano, nitro, trifluoromethyl, azido, -C (O) R11, -OC (O) R11, -NR11C (0) R12, -C (0) NR11R12, -NR1 R12, hydroxy, C1-C6 alkyl, alkoxy CrC6 , Ce-Cι aryl and 5-10 membered heteroaryl; each n independently represents an integer from 0 to 2; and each m independently represents an integer from 0 to 4. 2. The compound of claim 1, wherein X is -CH2NR7- or -NR7CHR6-, Z is a residue of formula b, R2 is OH, R3 is -OC (O) R14, R4 is OH and R6 is H. 3. The compound of claim 1, wherein X is -NR7CHR6-, Z is a residue of formula b, R2 and R6 are taken together to form a residue of formula d, R3 is -OC (O) R14, R4 is OH and R7 is CH3. 4. The compound of claim 1, wherein X, Y and R3 are taken together to form a moiety of formula a, Z is a moiety of formula b, R2 is OH and R4 is OH.
- 5. The compound of claim 1, wherein X is -CH2NR7 or -NR7CHR6-, Z is a residue of formula b, R2 and R3 are taken together to form a moiety of formula c, and R4 is OH.
- 6. The compound of claim 1, wherein X, Y and R3 are taken together to form a moiety of formula a, Z is -CH (OR8) -, R2 is -OR13 and R4 is OR15.
- 7. The compound of claim 1, wherein X, Y and R3 are taken together to form a moiety of formula a, Z is -C (O) -, R2 is -OR3 and R4 is OR15.
- 8. The compound of claim 7, wherein R1 is H; R5 is ethyl; R15 is H or methyl and R13 is a residue of the formulas e-q ff in which R19 is Ce-Cry aryl or 5-10 membered heteroaryl, wherein the aryl and heteroaryl moieties of the preceding R19 groups are optionally substituted with 1 to 3 substituents selected from the group consisting of halo, cyano , nitro, trifluoromethyl, azido -C (O) R11, -OC (O) R12, NR 1C (O) R12, -C (O) NR1 R12, -NR11R12, hydroxy, CrC6 alkyl) CrC6 alkoxy, aryl Ce-Cio and 5-10 membered heteroaryl.
- 9. The compound of claim 8, wherein R19 is selected from the group consisting of phenyl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8- quinolyl, 2-pyridyl, 3-pyridyl and 4-pyridyl.
- 10. The compound of claim 1, wherein R5 is selected from the group consisting of ethyl, isopropyl, cyclopropyl, sec-butyl, cyclobutyl, cyclopentyl, methylthioethyl, and furyl.
- 11. A method for preparing a compound of formula 2 wherein R2, R5, R9, R10 and R15 are defined herein, which comprises contacting a compound of formula f f with a Grignard reagent for a period of time and at a temperature sufficient to form a compound of formula 2.
- 12. - A method for preparing a compound of formula 4, wherein R5, R9, R10 and R15 are defined in this specification, which comprises contacting a compound of formula h with an amine oxidizing reagent for a period of time and at a temperature sufficient to form a compound of formula 4.
- 13. The method of claim 12, wherein the amine oxidizing reagent is selected from the group consisting of -bromo-succinimide, N-chloro-succinimide, iodine and bromine.
- 14. A method of preparing a compound of formula 5 wherein R2, R5, R9 and R10 are defined in this specification, which comprises contacting a compound of formula I with a Grignard reagent or a base for a period of time and at a temperature sufficient to form a compound of formula 5.
- 15. The method of claim 14, wherein the Grignard reagent is benzyl magnesium chloride or the base is (isopropyl-cyclohexyl-amino) -magnesium chloride.
- 16. A method of forming a compound of formula 7 wherein R2 and R5 are defined in this specification, which comprises contacting a compound of formula wherein R9 and R10 are defined in this specification, under acidic conditions for a period of time and at a temperature sufficient to form a compound of formula 7.
- 17. A pharmaceutical composition comprising a compound of formula 1 or one of its pharmaceutically acceptable salts, solvates or prodrugs and a pharmaceutically acceptable carrier.
- 18. The use of a compound of formula 1 or one of its pharmaceutically acceptable salts, solvates or prodrugs for the manufacture of a medicament for treating a bacterial or protozoal infection in a mammal, fish or bird.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/166,269 | 1999-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00011389A true MXPA00011389A (en) | 2002-06-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2359708C (en) | Ketolide antibiotics | |
US6159945A (en) | 9-amino-3-keto erythromycin derivatives | |
NO329629B1 (en) | 13-membered azalides | |
EP0992509B1 (en) | Novel macrolide derivatives | |
EP1132392B1 (en) | Ketolide antibiotics | |
US6518251B1 (en) | Macrolides | |
US6291656B1 (en) | Tricyclic erythromycin derivatives | |
US6262030B1 (en) | Erythromycin derivatives | |
EP1114826A2 (en) | Novel antibacterial and prokinetic macrolides | |
EP1167376B1 (en) | Macrolide antibiotics | |
JP2001213893A (en) | New 13- and 14-membered antibacterial and prokinetic macrolides and their intermediate | |
US20020061856A1 (en) | Novel tricyclic erythromycin derivatives | |
WO1998051696A1 (en) | Erythromycin derivatives | |
US20020077302A1 (en) | Tricyclic erythromycin derivatives | |
EP1115732B1 (en) | Carbamate and carbazate ketolide antibiotics | |
MXPA00011389A (en) | New macrolide | |
JP3432448B2 (en) | 9a, 11b-dehydro derivative of 9-oxime-3-keto-6-O-methylerythromycin | |
MXPA01007584A (en) | Ketolide antibiotics | |
EP1439186A2 (en) | Intermediates for novel antibacterial and prokinetic macrolides | |
MXPA01002355A (en) | Ketolide antibiotics | |
MXPA99009269A (en) | New derivatives of macroli | |
MXPA01000114A (en) | Novel antibacterial and prokinetic macrolides |